Stempoint Capital LP Has $1.28 Million Stock Holdings in uniQure N.V. $QURE

Stempoint Capital LP boosted its holdings in shares of uniQure N.V. (NASDAQ:QURE) by 79.5% in the first quarter, Holdings Channel reports. The firm owned 78,066 shares of the biotechnology company’s stock after purchasing an additional 34,581 shares during the quarter. Stempoint Capital LP’s holdings in uniQure were worth $1,276,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. raised its holdings in shares of uniQure by 5.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after buying an additional 533 shares in the last quarter. Arizona State Retirement System boosted its stake in uniQure by 6.0% in the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after buying an additional 627 shares in the last quarter. Ensign Peak Advisors Inc grew its position in uniQure by 21.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after acquiring an additional 650 shares during the period. CIBC Private Wealth Group LLC acquired a new position in uniQure during the third quarter worth $50,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in uniQure by 42.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 906 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently commented on QURE. Chardan Capital boosted their target price on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Barclays upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $25.00 to $65.00 in a research report on Thursday, June 18th. Weiss Ratings restated a “sell (e+)” rating on shares of uniQure in a research report on Friday, June 26th. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a research note on Tuesday, May 5th. Finally, HC Wainwright raised their price objective on shares of uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $64.17.

uniQure Price Performance

Shares of QURE stock opened at $40.07 on Thursday. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The stock has a market capitalization of $2.53 billion, a PE ratio of -11.51 and a beta of 0.90. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The stock’s fifty day moving average is $36.75 and its 200-day moving average is $26.01.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.50 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. During the same period in the prior year, the firm earned ($0.69) earnings per share. Equities research analysts expect that uniQure N.V. will post -3.39 EPS for the current fiscal year.

Insider Activity at uniQure

In other news, CEO Matthew C. Kapusta sold 21,082 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total transaction of $952,063.12. Following the transaction, the chief executive officer directly owned 519,227 shares in the company, valued at approximately $23,448,291.32. This represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 30,000 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total transaction of $1,392,600.00. Following the sale, the insider directly owned 148,235 shares in the company, valued at $6,881,068.70. This trade represents a 16.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 433,229 shares of company stock worth $17,944,799. 4.65% of the stock is owned by insiders.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.